Volume 29, Issue 3
DOI: 10.24205/03276716.2020.912
Efficacy of Transurethral Resection of Bladder Tumor for Superficial Bladder Cancer and Its Effect on The Prognosis
Abstract
Objective: This study aimed to explore the efficacy of transurethral resection of bladder tumor (TURBT) for superficial bladder cancer (BC) and its effect on the prognosis. Methods: We randomly assigned 116 patients with superficial BC admitted to our hospital to receive TURBT (69 cases, the research group, RG) or to receive conventional laparotomy (47 cases, the control group, CG). The two groups were compared in many terms, including the operation condition, the levels of inflammatory factors after treatment, the levels of serum indexes after treatment, treatment efficacy, the incidence of adverse reactions, the length of hospital stay, the quality of life, and the postoperative recurrence rate. Results: The operation time, intraoperative blood loss, and the catheter dwell time were lower in the RG than in the CG (P < 0.05). The expression levels of interleukin 10 (IL-10), interleukin 8 (IL-8), interleukin 6 (IL-6), and tumor necrosis factor (TNF-α) were lower in the RG than in the CG (P < 0.05). After treatment, the level of fibrinogen (Fib) was higher in RG than in CG (P < 0.05), while the levels of tumor-specific growth factor (TSGF) and hepatocyte growth factor (HGF) were lower in RG (P < 0.05). The treatment efficacy was superior in RG than in CG (P < 0.05). The incidence of adverse reactions was lower in RG than in CG (P < 0.05). The length of hospital stay was shorter in RG than in CG (P < 0.05). The quality of life score was markedly higher in RG than in CG (P < 0.05). The recurrence rate was lower in RG than in CG (P < 0.05).
Conclusion: TURBT showed superior efficacy in the treatment of superficial BC, with better postoperative recovery and lower recurrence rate, which is clinically valuable.
Keywords
Transurethral resection of bladder tumor, superficial bladder cancer, efficacy, prognosis